Trade Aytu BioScience, Inc. - AYTU CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.042
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021568 %(-$1.08)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.02157%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000654 %(-$0.03)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021568 %
  (-$1.08)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000654 %
  (-$0.03)

Key Stats

• Prev. Close: 2.104
• Open: 2.084
• 1-Year Change: -19.66%
• Day's Range: 2.034 - 2.124

Trade Aytu BioScience, Inc. - AYTU

About Aytu Biopharma Inc

Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.

Financial summary

BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.

Equity composition

Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.